These results indicate that abnormal activation of the NF-κB signaling pathway in osteoclasts is closely related to the activity of osteoclasts, and the inhibitory effect of CSP on the NF-κB pathway in osteoclasts is critical for the treatment of postmenopausal osteoporosis. Here, NFKB1 is linked to postmenopausal osteoporosis.